Diagnoptics News

What's new?

Read all news items about the AGE Reader, Diab-spot and DiagnOptics.

AGE Reader mu receives market approval in South Korea

Groningen, the Netherlands – February 27, 2018.

The AGE Reader mu has received medical device approval from the Korean Ministry of Food and Drug Safety (MFDS). This allows the Korean AGE Reader distributor, DiosPharma, to market the AGE Reader mu as a medical device.

Korean healthcare professionals are now allowed to use the AGE Reader mu in clinical practice. Immediately upon receiving the official regulatory approval DiosPharma successfully started the market introduction. Tim Souk, CEO of DiosPharma: “Recently, the Korean market is interested in AGE parameter from the media and the doctors. I am very excited and pleased to have registered the AGE Reader mu device at the right time. We have successfully held the first seminar in September in 2017 with the goal of selling more than 300 units in 2018.”

After receiving regulatory approval in China and Japan earlier, this approval in Korea is another milestone in the business development in Asia for Diagnoptics. Bart van den Berg, CEO of Diagnoptics, is confident that DiosPharma will be successful in marketing the AGE Reader: “Already from the first contact DiosPharma showed to be a professional and dedicated partner. By creating awareness about AGEs and obtaining this regulatory approval DiosPharma created a strong basis to build a promising business. This has immediately been confirmed by a first substantial order and more expected to come”.

Share this link on:

Latest news items

More Information
Request information

Would you like to learn more about our products? Request any information you wish to receive here.

AGE Reader mu
Non-invasive cardiovascular risk assessment
Age Reader MU
The AGE Reader mu is the next generation AGE Reader that combines a high measurement quality standard with an innovative design, at a reduced pricelevel. The AGE Reader mu is a perfect tool for diabetologists and family doctors. Read more »
Newsletter subscription

If you want to receive the newsletter with information about DiagnOptics' products, please send us your email address.

About the company

More information about Diagnoptics.

Information for patients

Information on Diagnoptics' products and Advanced Glycation Endproducts.

Information for professionals

Information about Advanced Glycation Endproducts, the AGE measurement and clinical validation.